Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $50,623 | 19 | 99.4% |
| Travel and Lodging | $327.97 | 1 | 0.6% |
| Unspecified | $0 | 3 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exeltis, USA Inc. | $13,923 | 7 | $0 (2024) |
| Evofem Biosciences, Inc. | $12,500 | 4 | $0 (2021) |
| Ferring International Center SA | $9,000 | 6 | $0 (2021) |
| MAYNE PHARMA INC. | $5,500 | 2 | $0 (2020) |
| Perrigo Company plc | $5,000 | 1 | $0 (2024) |
| Genentech, Inc. | $2,500 | 1 | $0 (2021) |
| Organon LLC | $2,200 | 1 | $0 (2023) |
| Medicines360 | $327.97 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,000 | 2 | Perrigo Company plc ($5,000) |
| 2023 | $5,028 | 3 | Exeltis, USA Inc. ($2,500) |
| 2021 | $4,000 | 4 | Genentech, Inc. ($2,500) |
| 2020 | $34,923 | 14 | Evofem Biosciences, Inc. ($12,500) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/17/2024 | Perrigo Company plc | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 07/05/2024 | Exeltis, USA Inc. | SLYND (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: CONTRACEPTIVE | ||||||
| 12/08/2023 | Exeltis, USA Inc. | SLYND (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Oral Contraceptive | ||||||
| 06/30/2023 | Medicines360 | Liletta (Device) | Travel and Lodging | Cash or cash equivalent | $327.97 | General |
| Category: Obstetrics/Gynecology (Women's Health) | ||||||
| 04/13/2023 | Organon LLC | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 06/08/2021 | Ferring International Center SA | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 03/24/2021 | Genentech, Inc. | TECENTRIQ (Biological) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: BioOncology | ||||||
| 2021 | Evofem Biosciences, Inc. | — | — | — | $0.00 | Ownership |
| 2021 | Evofem Biosciences, Inc. | — | — | — | $0.00 | Ownership |
| 12/21/2020 | Evofem Biosciences, Inc. | Phexxi (Drug) | Consulting Fee | Cash or cash equivalent | $12,500.00 | General |
| Category: Miscellaneous vaginal agent | ||||||
| 12/09/2020 | Exeltis, USA Inc. | SLYND (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Oral Contraceptive | ||||||
| 10/15/2020 | Ferring International Center SA | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 10/15/2020 | Exeltis, USA Inc. | SLYND (Drug) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: Oral Contraceptive | ||||||
| 08/12/2020 | Exeltis, USA Inc. | SLYND (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Oral Contraceptive | ||||||
| 06/18/2020 | Ferring International Center SA | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 05/13/2020 | Exeltis, USA Inc. | SLYND (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Oral Contraceptive | ||||||
| 04/09/2020 | MAYNE PHARMA INC. | E4/DRSP (Drug) | Consulting Fee | Cash or cash equivalent | $4,250.00 | General |
| Category: WOMEN'S HEALTH | ||||||
| 03/13/2020 | MAYNE PHARMA INC. | E4/DRSP (Drug) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: WOMEN'S HEALTH | ||||||
| 02/20/2020 | Exeltis, USA Inc. | SLYND (Drug) | Consulting Fee | Cash or cash equivalent | $3,297.87 | General |
| Category: Oral Contraceptive | ||||||
| 02/06/2020 | Ferring International Center SA | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 01/09/2020 | Ferring International Center SA | — | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| 01/09/2020 | Ferring International Center SA | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 2020 | Evofem Biosciences, Inc. | — | — | — | $0.00 | Ownership |
About Dr. Lisa Rarick, MD
Dr. Lisa Rarick, MD is a Obstetrics & Gynecology healthcare provider based in Chesapeake Beach, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2020. The National Provider Identifier (NPI) number assigned to this provider is 1770192825.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lisa Rarick, MD has received a total of $50,951 in payments from pharmaceutical and medical device companies, with $7,000 received in 2024. These payments were reported across 23 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($50,623).
Practice Information
- Specialty Obstetrics & Gynecology
- Location Chesapeake Beach, MD
- Active Since 07/24/2020
- Last Updated 07/24/2020
- Taxonomy Code 207V00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1770192825
Products in Payments
- SLYND (Drug) $13,923
- Phexxi (Drug) $12,500
- E4/DRSP (Drug) $5,500
- TECENTRIQ (Biological) $2,500
- Liletta (Device) $327.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.